Oric Pharmaceuticals (ORIC) Set to Post Quarterly Earnings on Thursday

Key Points

• Oric Pharmaceuticals is scheduled to report Q3 2026 results after market close Thursday, November 12; analysts expect a loss of about $0.38 per share. The earnings call is set for Friday, November 13, at 4:00 p.m. ET.
• The company’s last reported quarter missed consensus, posting a loss of $0.38 per share versus expectations of a $0.36 loss. Analysts forecast full-year EPS losses of $1.53 this year and $1.77 next year.
• Analyst sentiment is broadly positive: 14 analysts rate ORIC a Buy, with a consensus “Moderate Buy” rating and a $21.25 price target. Insiders sold 105,000 shares worth about $1.43 million over the past 90 days.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) is expected to be issuing its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.3836) per share for the quarter. Investors can find conference call details on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.02). On average, analysts expect Oric Pharmaceuticals to post ($1.53) EPS for the current fiscal year and ($1.77) EPS for the next fiscal year.

Oric Pharmaceuticals Price Performance

ORIC stock opened at $9.34 on Thursday. The company's 50-day simple moving average is $12.19 and its 200-day simple moving average is $11.12. Oric Pharmaceuticals has a 52-week low of $7.23 and a 52-week high of $14.68.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on ORIC shares. Stifel Nicolaus increased their price target on Oric Pharmaceuticals from $14.00 to $18.00 and gave the stock a "buy" rating in a research report on Monday, October 26th. HC Wainwright boosted their price objective on Oric Pharmaceuticals from $25.00 to $27.00 and gave the company a "buy" rating in a research report on Monday, August 10th. BTIG Research reaffirmed a "buy" rating and set a $26.00 target price on shares of Oric Pharmaceuticals in a research note on Wednesday, October 28th. Leerink Partners started coverage on Oric Pharmaceuticals in a research report on Monday, October 5th. They set an "outperform" rating and a $26.00 target price on the stock. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Oric Pharmaceuticals in a report on Thursday, October 15th. Fourteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Oric Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $21.25.

Insider Transactions at Oric Pharmaceuticals

In other Oric Pharmaceuticals news, CFO Dominic Piscitelli sold 14,000 shares of the business's stock in a transaction that occurred on Tuesday, October 20th. The stock was sold at an average price of $13.53, for a total transaction of $189,420.00. Following the completion of the sale, the chief financial officer directly owned 69,828 shares in the company, valued at approximately $944,772.84. The trade was a 16.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 105,000 shares of company stock valued at $1,432,952. Insiders own 5.70% of the company's stock.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc NASDAQ: ORIC is a clinical-stage biopharmaceutical company focused on developing medicines that overcome mechanisms of treatment resistance in cancer. The company uses its discovery platform to identify therapies intended to improve or restore the effectiveness of existing cancer treatments.

Oric's pipeline has included ORIC-533, an oral small-molecule inhibitor of CD73 designed to block adenosine-mediated immunosuppression in the tumor microenvironment. The company has evaluated the program in hematologic malignancies, including multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.